Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Yidu TechFRA:0EL -0.40%72 10-Year RORE % is 0.00 as of Mar. 2026. GuruFocus rates FRA:0EL with a GF Score™ of 72/100 and a GF Value™ of €0.67 (Modestly Undervalued). The stock has 7 warning signs investors should review. Among 321 Healthcare Providers & Services companies, Yidu Tech ranks worse than 311526.17% on this metric.
Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments.
Yidu Tech does not have enough data to calculate 10-Year RORE %.
Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.
There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 10-year period is chosen.
Be Aware
Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.
Yidu Tech 10-Year RORE % Related Terms
Yidu Tech 10-Year RORE % Historical Data
* Premium members only.
The historical data trend for Yidu Tech's 10-Year RORE % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:0EL vs VEEV, BTSG, HQY: 10-Year RORE % Comparison
For the Health Information Services subindustry, Yidu Tech's 10-Year RORE %, along with its competitors' market caps and 10-Year RORE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Yidu Tech 10-Year RORE % vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Yidu Tech's 10-Year RORE % distribution charts can be found below:
* The bar in red indicates where Yidu Tech's 10-Year RORE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of 10-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Mar. 2026 and 10-year before.
Yidu Tech (FRA:0EL) has a 10-Year RORE % of 0.00 as of Mar. 2026. 10-Year RORE % shows how much a company earns by reinvesting its retained earnings in 10-year. View historical data on Yidu Tech and its competitors. According to the industry distribution chart, Yidu Tech ranks #999999 out of 321 companies in the Healthcare Providers & Services industry.
Is Yidu Tech's 10-Year RORE % too high?
Yidu Tech's current 10-Year RORE % is 0.00. Based on the distribution chart, Yidu Tech ranks #999999 out of 321 companies in the Healthcare Providers & Services industry, which is in the bottom quartile relative to peers. Overall, Yidu Tech has a GF Score™ of 72/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Yidu Tech's 10-Year RORE % compare to VEEV and BTSG?
According to the Healthcare Providers & Services industry distribution chart, Yidu Tech ranks #999999 out of 321 companies for 10-Year RORE %. This places Yidu Tech in the lower half of its industry. The industry median 10-Year RORE % is 7.08. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 10-Year RORE % for a Healthcare Providers & Services company?
The median 10-Year RORE % among Healthcare Providers & Services companies is 7.08, based on 321 companies in the industry. Companies in the top quartile (top 25%) have a 10-Year RORE % significantly above this median, while those in the bottom quartile fall well below. However, 10-Year RORE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 10-Year RORE % mean?
A high 10-Year RORE % can signal that a stock is expensive relative to its fundamentals. 10-Year RORE % shows how much a company earns by reinvesting its retained earnings in 10-year. View historical data on Yidu Tech and its competitors. For the Healthcare Providers & Services industry, the median 10-Year RORE % is 7.08 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Yidu Tech's current 10-Year RORE % is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Yidu Tech stock overvalued right now?
Based on GuruFocus' analysis, Yidu Tech (FRA:0EL) is currently considered Modestly Undervalued. The stock's GF Value™ is €0.67, compared to a current price of €0.50 — trading 25.7% below its estimated fair value. The current 10-Year RORE % is 0.00. Yidu Tech's overall GF Score™ is 72/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 10-Year RORE % calculated?
10-Year RORE % is calculated from a company's financial statements. For Yidu Tech (FRA:0EL), the current 10-Year RORE % is 0.00 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Yidu Tech (FRA:0EL) Overvalued in 2026?
Based on GuruFocus' analysis, Yidu Tech stock appears to be undervalued.
The current stock price of €0.50 is trading 25.7% below its estimated GF Value™ of €0.67.
GuruFocus considers Yidu Tech to be Modestly Undervalued.
Key valuation signals for FRA:0EL:
10-Year RORE %: 0.00
GF Value™: €0.67 vs. price of €0.50 (25.7% below fair value)
No single metric tells the full story. See the FRA:0EL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Yidu Tech Inc offers healthcare solutions built on big data and artificial intelligence (AI) technologies. The company serves various healthcare industry participants, including hospitals, pharmaceutical, biotech, research institutions, insurance companies, etc. Its operating segments are: Big data platform and solutions, Life sciences solutions, and Health management platform and solutions. The majority of the company's revenue is generated from its Big data platform and solutions segment, which provides data intelligence platforms and data analytics-driven solutions (such as Eywa 5.0, Lingxi Intelligent Management, AI Middleware, etc.) for hospitals, healthcare institutions, regulators, and policymakers. Geographically, the company generates maximum revenue from Mainland China.
72GF Score
Get the complete analysis for FRA:0EL
10-Year RORE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:0EL has been successfully added to your 
